Dr. Torrejon, the original founder of Humonix, replaces Kimberly Southern

Specialty pharmaceutical research company’s new retinal vascular dysfunction model can have a major impact on research and development of new drugs for retinal vascular diseases.

Specialty pharmaceutical research company celebrates the launch of a new service offering and with it, a brand refresh.

The in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy

3D Human Tissue Retina Vasculature model provides a new and novel approach to rapidly and efficiently screening numerous therapies for diabetic retinopathy and diabetic macular edema.

Appointment reflects Glauconix Biosciences' expansion of their 3D Human Tissue model platform within the Ophthalmology space and brings their second commercial model closer to market